Evercore ISI lowered the firm’s price target on Boston Scientific (BSX) to $110 from $115 and keeps an Outperform rating on the shares, which the analyst added to the firm’s “Tactical Outperform” list. Fears over EP market share shifts and a sector rotation into life science tools have hurt the stock, though a “bullish” analyst day should allay fears, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific downgraded to Hold from Buy at Erste Group
- Boston Scientific price target raised to $136 from $133 at Barclays
- Top 3 Trending Stocks, According to Analysts – 10/1/2025
- Boston Scientific call volume above normal and directionally bullish
- Boston Scientific price target raised to $129 from $125 at Truist